Clinical Trial Initiations, Conferences Participations, Strategic Collaborations, and Presentation of New Pre-Clinical Data - Research Report on Biogen Idec, BioMarin, Medivation, Cytori, and Alnylam

NEW YORK, November 8, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Biogen Idec Inc. (NASDAQ: BIIB), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Medivation, Inc. (NASDAQ: MDVN), Cytori Therapeutics, Inc. (NASDAQ: CYTX), and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Biogen Idec Inc. Research Report

On November 5, 2013, Biogen Idec Inc. (Biogen Idec) announced that it is scheduled to present at the Credit Suisse Global Healthcare Conference on Tuesday, November 12, 2013, at 8:30 a.m. MST / 10:30 a.m. ET. The Company informed that a live webcast of the presentation can be accessed by interested parties through the Company's website. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/b95b_BIIB]

--

BioMarin Pharmaceutical Inc. Research Report

On October 31, 2013, BioMarin Pharmaceutical Inc. (BioMarin) announced that it has initiated its Phase 3 Trial for BMN 673 for the treatment of metastatic germline BRCA muted breast cancer. BioMarin informed that it has dosed the first patient in the Phase 3 program to evaluate its poly ADP-ribose polymerase (PARP) inhibitor, BMN 673. According to the Company, the Phase 3 study is an open-label, randomized, parallel, two-arm, multi-center study of BMN 673, against physician's choice in approximately 430 germline BRCA mutation patients with locally advanced and/or metastatic breast cancer, who have received no more than two prior chemotherapy regimens for metastatic disease. "We are eager to fully enroll this important trial for breast cancer patients with hereditary breast cancer to better understand the role of BMN 673 in this defined population," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin. "We are looking forward to gaining a better understanding of the safety and efficacy of our compound." The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/9b6c_BMRN]

--

Medivation, Inc. Research Report  

On October 30, 2013, Medivation, Inc. (Medivation) announced its scheduled participation at two upcoming investor conferences in November 2013. According to the Company, its M.D, President and CEO, David, Hung will represent Medivation at the Credit Suisse Healthcare Conference on Wednesday, November 13, 2013, at 1:30 p.m. at the Phoenician Hotel in Scottsdale, Arizona; and at the Jefferies 2013 London Healthcare Conference on Wednesday November 20, 2013, at 2:20 p.m. at the Waldorf Hilton in London. The Company informed that interested individuals may access the live audio webcast of the presentations at the Company's website. The Full Research Report on Medivation, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4277_MDVN]

--

Cytori Therapeutics, Inc. Research Report

On November 4, 2013, Cytori Therapeutics Inc. (Cytori) and Lorem Vascular jointly announced its strategic collaboration to commercialize Cytori Cell Therapy for the cardiovascular, renal and diabetes markets in China, Hong Kong, Malaysia, Singapore and Australia. According to the Company, under the terms of agreement, Lorem Vascular will pay $531 million in license fees, opening product purchase commitments and Cytori equity purchases. "Through this agreement with Lorem Vascular, we have secured a committed partner to bring Cytori Cell Therapy to patients in countries where we have recently received, or are in the process of achieving, regulatory approval," said Christopher J. Calhoun, CEO of Cytori. "With the Celution® System now approved and available in more than 40 countries, we are uniquely positioned to expand our cell therapy brand by being first-to-market with cell therapy products in new geographies around the world. Lorem Vascular brings to Cytori the required resources, market knowledge, dedication and focus to commercialize this innovative treatment and pioneer the introduction of cell therapy products for patients with the most serious conditions." The Full Research Report on Cytori Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/e1ae_CYTX]

--

Alnylam Pharmaceuticals, Inc. Research Report  

On November 2, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced its presentation of a new pre-clinical data with ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in development for the treatment of liver disease associated with AAT deficiency. According to the Company, Alnylam scientists and collaborators presented new results in a transgenic mouse model of Z-AAT protein over-expression showing that subcutaneous administration of a GalNAc-siRNA targeting AAT led to rapid, potent, dose-dependent, and durable knockdown of AAT of greater than 90%, as well as a significant reduction in fibrosis and the incidence of liver tumors. Rachel Meyers, Ph.D., Vice President of Research and RNAi Lead Development at Alnylam said, "Our new pre-clinical data with a GalNAc-siRNA conjugate against AAT demonstrate rapid, potent, dose-dependent, and durable knockdown of AAT to greater than 90% resulting in a significant reduction of liver fibrosis and tumor formation. If these results extend in clinical studies, we believe that ALN-AAT could become an important treatment option for the management of disease in people with AAT deficiency." The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/5b29_ALNY]

---

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner